We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ACA:EURONEXT PARISCredit Agricole SA Analysis

Data as of 2026-05-19 - not real-time

$117.68

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Arcosa is trading at $117.68, below its 20‑day SMA of 124.36 but comfortably above the 50‑day (114.51) and 200‑day (106.71) averages, suggesting a mild pull‑back within an overall bullish framework. The RSI sits at 43.8, indicating a neutral momentum zone, while a negative MACD histogram signals short‑term bearish pressure. Volume has been decreasing and 30‑day volatility is elevated at roughly 44%, underscoring near‑term price fragility, yet the stock remains above the identified support level of $115.55 and offers an estimated upside of about 20% toward the consensus 12‑month target of $141.
Fundamentally, the company delivered a 4.4% YoY revenue increase to $2.9 bn, with EBITDA climbing to $543 m and margins (gross 22.7%, operating 8.6%) solid for its sector. A forward PE of 23.3 sits below the industry average of 29.3, indicating relative undervaluation, and the modest 0.16% dividend yield is underpinned by a very low payout ratio (~4.5%), making it sustainable. Recent Q1 earnings beat expectations, reporting EPS of $0.77 and strong EBITDA growth, while management raised full‑year guidance, positioning the stock for a measured rally despite a beta near 1.4 and a high fear‑greed index of Extreme Greed.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price hovering just above the $115.55 support level
  • bearish MACD histogram indicating short‑term downside pressure
  • decreasing volume combined with high 30‑day volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • PE multiple below industry average suggesting undervaluation
  • Q1 earnings beat and raised full‑year guidance
  • estimated 20% upside toward the $141 analyst target

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • sustainable dividend supported by a low payout ratio
  • strategic divestitures improving the balance sheet
  • stable cash flow and long‑term demand for infrastructure solutions

Key Metrics & Analysis

Financial Health

Revenue Growth4.40%
Profit Margin7.66%
P/E Ratio26.3
ROE8.62%
ROA4.00%
Debt/Equity59.55
P/B Ratio2.2
Op. Cash Flow$413.7M
Free Cash Flow$55.3M
Industry P/E29.3

Technical Analysis

TrendBullish
RSI43.8
Support$115.55
Resistance$135.58
MA 20$124.36
MA 50$114.51
MA 200$106.71
MACDBearish
VolumeDecreasing
Fear & Greed Index89.14

Valuation

Target Price$141.00
Upside/Downside19.82%
GradeUndervalued
TypeBlend
Dividend Yield0.16%

Risk Assessment

Beta1.44
Volatility43.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.